AbbVie
US.ABBV
256.46
-3.75
-1.44%
AbbVie
256.46
-3.75
-1.44%
Live - 104 symbols - heartbeat 173s ago
· 2026-09-04 20:02
Pre-market
259.19
-0.39%
After-hours
256.53
+0.03%
Overnight
259.13
-0.42%
Revenue annual, last 8 years
Latest year +8.57% YoY
Margins
- Gross margin
- 70.24%
- Operating margin
- 32.85%
- Net margin
- 6.84%
Key ratios & quality
- Enterprise value
- 515.43B
- Altman Z-Score
- 2.64
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
✦ Quant Financial Health how this is computed
Fair
- Altman Z-Score is 2.64, in the 1.8-3.0 "grey zone".
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 32.75B | 33.27B | 45.80B | 56.20B | 58.05B | 54.32B | 56.33B | 61.16B |
| Gross profit | 25.04B | 25.83B | 30.42B | 38.75B | 40.64B | 33.90B | 39.43B | 42.96B |
| Selling & admin expenses | 7.40B | 6.94B | 11.30B | 12.35B | 15.26B | 12.87B | 14.75B | 14.01B |
| Research & development | 10.75B | 6.79B | 7.76B | 8.05B | 6.51B | 7.68B | 12.79B | 9.10B |
| Operating profit | 6.38B | 12.98B | 11.36B | 17.92B | 18.81B | 13.54B | 11.89B | 20.09B |
| Pretax profit | 5.20B | 8.43B | 3.40B | 12.99B | 13.48B | 6.25B | 3.72B | 6.60B |
| Tax | -490.00M | 544.00M | -1.22B | 1.44B | 1.63B | 1.38B | -570.00M | 2.36B |
| Net profit | 5.69B | 7.88B | 4.62B | 11.55B | 11.85B | 4.87B | 4.29B | 4.23B |
| Basic EPS | 4 | 5 | 3 | 6 | 7 | 3 | 2 | 2 |
| Diluted EPS | 3.66 | 5.28 | 2.72 | 6.45 | 6.63 | 2.72 | 2.39 | 2.37 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 13.34B | 15.42B | 15.78B | 16.62B | 15.00B | 16.99B |
| Gross profit | 9.34B | 11.08B | 10.47B | 12.07B | 10.78B | 12.70B |
| Selling & admin expenses | 3.29B | 3.25B | 3.57B | 3.90B | 3.58B | 3.63B |
| Research & development | 2.07B | 2.13B | 2.32B | 2.58B | 2.47B | 2.34B |
| Operating profit | 3.98B | 5.72B | 4.58B | 5.81B | 4.73B | 6.72B |
| Pretax profit | 1.66B | 1.55B | 714.00M | 2.67B | 1.04B | 4.28B |
| Tax | 372.00M | 613.00M | 526.00M | 853.00M | 342.00M | 662.00M |
| Net profit | 1.29B | 941.00M | 188.00M | 1.82B | 697.00M | 3.62B |
| Basic EPS | 1 | 1 | 0 | 1 | 0 | 2 |
| Diluted EPS | 0.72 | 0.52 | 0.10 | 1.02 | 0.39 | 2.03 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 16.95B | 49.52B | 24.17B | 27.93B | 28.46B | 33.00B | 25.58B | 29.06B |
| Cash & ST investments | 8.06B | 39.92B | 8.48B | 9.83B | 9.23B | 12.82B | 5.56B | 5.26B |
| Inventory | 1.61B | 1.81B | 3.31B | 3.13B | 3.58B | 4.10B | 4.18B | 4.95B |
| Total assets | 59.35B | 89.12B | 150.57B | 146.53B | 138.81B | 134.71B | 135.16B | 133.96B |
| Total current liabilities | 17.24B | 15.59B | 28.66B | 35.19B | 29.54B | 37.84B | 38.75B | 43.29B |
| Short-term debt | 5.31B | 3.75B | 8.50B | 12.50B | 4.14B | 7.19B | 6.80B | 8.56B |
| Long-term debt | 35.00B | 62.98B | 77.55B | 64.19B | 59.14B | 52.19B | 60.34B | 58.94B |
| Total liabilities | 67,798,000,000.00 | 97,287,000,000.00 | 137,468,000,000.00 | 131,093,000,000.00 | 121,518,000,000.00 | 124,314,000,000.00 | 131,797,000,000.00 | 137,188,000,000.00 |
| Total equity | -8.45B | -8.17B | 13.10B | 15.44B | 17.29B | 10.40B | 3.36B | -3.23B |
| Retained earnings | 3.37B | 4.72B | 1.06B | 3.13B | 4.78B | -1.00B | -7.90B | -15.49B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 27.68B | 29.26B | 28.54B | 29.06B | 33.53B | 33.67B |
| Cash & ST investments | 5.18B | 6.47B | 5.67B | 5.26B | 9.39B | 6.57B |
| Inventory | 4.53B | 4.96B | 4.94B | 4.95B | 5.05B | 5.13B |
| Total assets | 136.17B | 137.18B | 133.90B | 133.96B | 136.46B | 135.12B |
| Total current liabilities | 36.40B | 39.77B | 39.39B | 43.29B | 42.10B | 41.64B |
| Short-term debt | 5.36B | 7.52B | 5.77B | 8.56B | 8.33B | 8.34B |
| Long-term debt | 64.53B | 62.96B | 62.97B | 58.94B | 64.53B | 62.48B |
| Total liabilities | 134,703,000,000.00 | 137,320,000,000.00 | 136,497,000,000.00 | 137,188,000,000.00 | 143,075,000,000.00 | 141,003,000,000.00 |
| Total equity | 1.46B | -138.00M | -2.60B | -3.23B | -6.61B | -5.89B |
| Retained earnings | -9.53B | -11.50B | -14.23B | -15.49B | -17.87B | -17.33B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 13.43B | 13.32B | 17.59B | 22.78B | 24.94B | 22.84B | 18.81B | 19.03B |
| Depreciation & amortization | 1.77B | 2.02B | 6.47B | 8.52B | 8.47B | 8.70B | 8.39B | 8.14B |
| Free cash flow | 12.79B | 12.77B | 16.79B | 21.99B | 24.25B | 22.06B | 17.83B | 17.82B |
| Dividends paid | -5.58B | -6.37B | -7.72B | -9.26B | -10.04B | -10.54B | -11.03B | -11.66B |
| Stock buybacks / issuance | -12.01B | -629.00M | -978.00M | -934.00M | -1.49B | -1.97B | -1.71B | -980.00M |
| Ending cash balance | 7.29B | 39.92B | 8.45B | 9.75B | 9.20B | 12.81B | 5.52B | 5.23B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 1.64B | 5.15B | 7.02B | 5.22B | 3.83B | 3.44B |
| Depreciation & amortization | 2.04B | 2.05B | 2.06B | 1.99B | 1.94B | 1.88B |
| Free cash flow | 1.40B | 4.88B | 6.64B | 4.89B | 3.56B | 3.11B |
| Dividends paid | -2.93B | -2.91B | -2.91B | -2.91B | -3.09B | -3.07B |
| Stock buybacks / issuance | -961.00M | -12.00M | -4.00M | -3.00M | -1.49B | -9.00M |
| Ending cash balance | 5.18B | 6.47B | 5.63B | 5.23B | 9.39B | 6.57B |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE % | -- | -- | 185.81 | 80.52 | 72.15 | 34.91 | 61.94 | 15,221.82 |
| ROA % | 8.69 | 10.56 | 3.80 | 7.72 | 8.26 | 3.52 | 3.14 | 3.11 |
| ROIC % | -- | -- | 7.89 | 14.21 | 15.73 | 8.16 | 8.48 | 8.72 |
| 5-year avg ROE % | -- | -- | -- | -- | -- | -- | 87.06 | 3,094.27 |
| EBIT margin % | 19.98 | 30.69 | 12.78 | 27.43 | 27.06 | 15.60 | 11.58 | 15.52 |
| FCF / sales % | 39.05 | 38.39 | 36.66 | 39.13 | 41.77 | 40.62 | 31.65 | 29.13 |
| Current ratio | 0.98 | 3.18 | 0.84 | 0.79 | 0.96 | 0.87 | 0.66 | 0.67 |
| Quick ratio | 0.78 | 2.91 | 0.60 | 0.56 | 0.69 | 0.63 | 0.43 | 0.41 |
| Debt / assets | -- | -- | 658.12 | 497.69 | 366.70 | 573.21 | 2,019.37 | -- |
| LT debt / equity | -- | -- | 593.10 | 416.60 | 342.73 | 503.80 | 1,814.74 | -- |
| Interest coverage | 4.86 | 5.72 | 2.38 | 6.36 | 7.04 | 3.81 | 2.32 | 3.28 |
| Revenue CAGR (3Y) % | 12.74 | 9.07 | 17.53 | 19.72 | 20.40 | 5.85 | 0.08 | 1.75 |
| Net income CAGR (3Y) % | 3.40 | 9.81 | -4.56 | 26.61 | 14.51 | 1.75 | -28.17 | -29.06 |
| FCF CAGR (3Y) % | 22.23 | 24.86 | 21.20 | 19.80 | 23.82 | 9.53 | -6.75 | -9.76 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE % | 88.15 | 112.90 | 138.53 | 15,221.82 | -- | -- |
| ROA % | 2.92 | 2.67 | 1.69 | 3.11 | 2.64 | 4.61 |
| ROIC % | 7.83 | 7.72 | 6.13 | 8.72 | -- | -- |
| 5-year avg ROE % | -- | -- | -- | -- | -- | -- |
| EBIT margin % | 11.28 | 10.10 | 7.61 | 15.52 | 14.14 | 18.04 |
| FCF / sales % | 26.82 | 31.27 | 33.00 | 29.13 | 31.81 | 28.28 |
| Current ratio | 0.76 | 0.74 | 0.72 | 0.67 | 0.80 | 0.81 |
| Quick ratio | 0.48 | 0.48 | 0.47 | 0.41 | 0.52 | 0.49 |
| Debt / assets | 4,921.76 | -- | -- | -- | -- | -- |
| LT debt / equity | 4,544.15 | -- | -- | -- | -- | -- |
| Interest coverage | 2.27 | 2.06 | 1.58 | 3.28 | 3.05 | 3.98 |
| Revenue CAGR (3Y) % | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) % | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) % | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
SKYRIZI32.40%
Other17.37%
RINVOQ14.86%
All other6.53%
Vraylar6.30%
Botox Therapeutic6.13%
VENCLEXTA4.54%
HUMIRA4.45%
Botox Cosmetic4.28%
IMBRUVICA3.13%
Quote time 2026-09-04 20:02:13
For reference only, not investment advice.